当前位置: X-MOL 学术Annu. Rev. Virol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus
Annual Review of Virology ( IF 11.3 ) Pub Date : 2017-09-29 00:00:00 , DOI: 10.1146/annurev-virology-101416-041929
Maham Ahmad 1 , Osama M. Ahmed 2 , Bruce Schnepp 3 , Philip R. Johnson 3
Affiliation  

This review discusses recent progress made in developing a vaccine and novel treatments for human immunodeficiency virus (HIV). It highlights the shortcomings of the RV144 vaccination trial [ALVAC-HIV (vCP1521) and AIDSVAX B/E] and the current standard of care and proposes that engineered expression of broadly neutralizing antibodies (bNAbs) against HIV-1 could overcome these shortcomings. Current developments in three major lines of research on HIV prevention and treatment using bNAbs are reviewed: firstly, the use of sequential immunogens to activate B cells to express bNAbs; secondly, the delivery of novel and extremely potent bNAbs through passive administration; and finally, the use of gene transfer using adeno-associated viral vectors to deliver bNAbs.

中文翻译:


针对人类免疫缺陷病毒的广泛中和抗体的工程表达

这篇综述讨论了开发针对人类免疫缺陷病毒(HIV)的疫苗和新疗法的最新进展。它强调了RV144疫苗接种试验[ALVAC-HIV(vCP1521)和AIDSVAX B / E]的缺点以及当前的护理标准,并提出了针对HIV-1的广泛中和抗体(bNAb)的工程表达可以克服这些缺点。综述了使用bNAb预防和治疗HIV的三个主要研究领域的最新进展:首先,使用顺序免疫原激活B细胞来表达bNAb。其次,通过被动给药来递送新颖且功能强大的bNAb。最后,利用腺相关病毒载体进行基因转移来递送bNAb。

更新日期:2017-09-29
down
wechat
bug